Moxifloxacin HCL Prices are Surging In India

Ex-Vapi, India: Moxifloxacin HCL prices recorded a sudden upsurged price trajectory in Indian Market. The primary factor influencing the Moxifloxacin HCL price was higher demands from the downstream Domestic Market. Furthermore, the increasing exporting activity from India to various other regions influenced the API Market.

This increase in downstream demand for the treatment of antibacterial infections and supply deficiency backed by a lack of Upstream feed sulfonic acid in the Market affects the price value of API.

Moxifloxacin HCL exporting activity from INDIA – a significant exporter of API to various other regions, was insufficient to meet the surging demand, resulting in constraining its Supply chain. Moreover, the importing frequency has also been affected owing to soaring Covid-19 cases in China, leading to port congestion and temporary shutdown in its various states.

Moxifloxacin HCL API prices were recorded with a monthly inclination of 12.47% in the Indian Market at the end of June 2022. The Upstream feed sulfonic acid cost has been rising both regionally and domestically. However, the reduction in sufficient supplies and insufficient feedstock inventories in the Market caused the manufacturers to boost their production momentum in the units. Also, surging fuel costs owing to rerouting activities added another factor to the price enhancement of Moxifloxacin HCL prices.

Additionally, in India, due to upsurged Covid cases, the demand for Moxifloxacin HCL increased from end-users as it is preferred for its application in the treatment of Bacterial diseases such as respiratory and urinary tract infection and pneumonia, driving the Market of Moxifloxacin HCL API.

According to Chemanalyst: "Due to the interrupted supply and difficulty in the availability of raw materials, Moxifloxacin HCL prices might increase in forthcoming months. It is expected that the cost of Moxifloxacin HCL will continue to increase till the end of July, and this movement will continue until and unless the supply flow of Moxifloxacin improves in the country; with sufficient inventories for feedstock."